The Comparative Efficacy of L-glutamine, Celecoxib, and Glucosamine Sulfate in Osteoarthritis Management

Overview

Journal Sci Rep

Specialty Science

Date 2025 Mar 16

PMID 40089639

Authors

Zhongyao Hu

Changming Wang

Chen Wang

Junyan He

Yiqun Yan

Zelin Xu

Yangmang Yu

Ya Yu

Huan Cheng

Lei Liu

Miao Tang

Chun Zhang

Haoran Yu

Juehua Jing

Wendan Cheng

Affiliations

Soon will be listed here.

Abstract

To explore the therapeutic efficacy of L-glutamine (L-Gln) on pathological progression and clinical symptoms of osteoarthritis (OA), and compare with glucosamine sulfate (GS), and celecoxib (CXB). Rats were administered sodium chloride, L-Gln, GS, or CXB via gavage for eight weeks starting from the fifth week after sham operation or Anterior Cruciate Ligament Transection (ACLT) + Medial Meniscectomy (MMx). Then the severity of knee OA in rats was evaluated by serological analysis, histological examination and imaging examination. In addition, patients with mild primary OA were administered L-Gln, GS, or CXB orally for 12 weeks in accordance with the randomization principle. The efficacy end points were the change from baseline to week 24 in the pain and physical function subscale scores of the Western Ontario and McMaster Universities OA Index (WOMAC), and Lequesne score. Treatment with L-Gln alleviated the increased concentration of serum cartilage degradation markers caused by OA in rats. Histological tests showed improvement in knee joint cartilage destruction after treatment. Three-dimensional CT scans and reconstructions revealed a reduction in osteophyte formation and subchondral bone loss. L-glutamine performed as well as or better than glucosamine sulfate and celecoxib in all comparative measures among the three treatment groups. In clinical trials, the WOMAC pain and physical function subscale scores, as well as the Lequesne score, decreased from baseline in all three patient groups during follow-up, with no significant differences observed between the groups. Our research indicates that L-Gln is comparable to GS and CXB in improving the pathological progression and clinical efficacy of OA, which makes it a promising drug for the treatment of osteoarthritis.

References

Abramoff B, Caldera F . Osteoarthritis: Pathology, Diagnosis, and Treatment Options. Med Clin North Am. 2020; 104(2):293-311. DOI: 10.1016/j.mcna.2019.10.007. View

Sharma L . Osteoarthritis of the Knee. N Engl J Med. 2021; 384(1):51-59. DOI: 10.1056/NEJMcp1903768. View

Lotz M, Carames B . Autophagy and cartilage homeostasis mechanisms in joint health, aging and OA. Nat Rev Rheumatol. 2011; 7(10):579-87. PMC: 3192496. DOI: 10.1038/nrrheum.2011.109. View

Glyn-Jones S, Palmer A, Agricola R, Price A, Vincent T, Weinans H . Osteoarthritis. Lancet. 2015; 386(9991):376-87. DOI: 10.1016/S0140-6736(14)60802-3. View

Hunter D . Pharmacologic therapy for osteoarthritis--the era of disease modification. Nat Rev Rheumatol. 2010; 7(1):13-22. DOI: 10.1038/nrrheum.2010.178. View

Guo H, Yin W, Zou Z, Zhang C, Sun M, Min L . Quercitrin alleviates cartilage extracellular matrix degradation and delays ACLT rat osteoarthritis development: An in vivo and in vitro study. J Adv Res. 2020; 28:255-267. PMC: 7753236. DOI: 10.1016/j.jare.2020.06.020. View

Cruzat V, Rogero M, Keane K, Curi R, Newsholme P . Glutamine: Metabolism and Immune Function, Supplementation and Clinical Translation. Nutrients. 2018; 10(11). PMC: 6266414. DOI: 10.3390/nu10111564. View

Roth E . Nonnutritive effects of glutamine. J Nutr. 2008; 138(10):2025S-2031S. DOI: 10.1093/jn/138.10.2025S. View

Curi R, Lagranha C, Doi S, Sellitti D, Procopio J, Pithon-Curi T . Molecular mechanisms of glutamine action. J Cell Physiol. 2005; 204(2):392-401. DOI: 10.1002/jcp.20339. View

10.

Choi K, Lee S, Oh S, Lim S, Lim S, Jeon W . The effect of oral glutamine on 5-fluorouracil/leucovorin-induced mucositis/stomatitis assessed by intestinal permeability test. Clin Nutr. 2006; 26(1):57-62. DOI: 10.1016/j.clnu.2006.07.003. View

11.

Peterson D, Jones J, Petit 2nd R . Randomized, placebo-controlled trial of Saforis for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy. Cancer. 2006; 109(2):322-31. DOI: 10.1002/cncr.22384. View

12.

Niihara Y, Miller S, Kanter J, Lanzkron S, Smith W, Hsu L . A Phase 3 Trial of l-Glutamine in Sickle Cell Disease. N Engl J Med. 2018; 379(3):226-235. DOI: 10.1056/NEJMoa1715971. View

13.

Senkal M, Haaker R, Deska T, Hummel T, Steinfort C, Zumtobel V . Early enteral gut feeding with conditionally indispensable pharmaconutrients is metabolically safe and is well tolerated in postoperative cancer patients--a pilot study. Clin Nutr. 2004; 23(5):1193-8. DOI: 10.1016/j.clnu.2004.03.010. View

14.

Garlick P . Assessment of the safety of glutamine and other amino acids. J Nutr. 2001; 131(9 Suppl):2556S-61S. DOI: 10.1093/jn/131.9.2556S. View

15.

Kronenberg H . Developmental regulation of the growth plate. Nature. 2003; 423(6937):332-6. DOI: 10.1038/nature01657. View

16.

Stegen S, Rinaldi G, Loopmans S, Stockmans I, Moermans K, Thienpont B . Glutamine Metabolism Controls Chondrocyte Identity and Function. Dev Cell. 2020; 53(5):530-544.e8. DOI: 10.1016/j.devcel.2020.05.001. View

17.

Arra M, Swarnkar G, Adapala N, Naqvi S, Cai L, Rai M . Glutamine metabolism modulates chondrocyte inflammatory response. Elife. 2022; 11. PMC: 9371604. DOI: 10.7554/eLife.80725. View

18.

Anderson J, Chokesuwattanaskul S, Phelan M, Welting T, Lian L, Peffers M . H NMR Metabolomics Identifies Underlying Inflammatory Pathology in Osteoarthritis and Rheumatoid Arthritis Synovial Joints. J Proteome Res. 2018; 17(11):3780-3790. PMC: 6220363. DOI: 10.1021/acs.jproteome.8b00455. View

19.

Zhang Z, Huang C, Jiang Q, Zheng Y, Liu Y, Liu S . Guidelines for the diagnosis and treatment of osteoarthritis in China (2019 edition). Ann Transl Med. 2020; 8(19):1213. PMC: 7607097. DOI: 10.21037/atm-20-4665. View

20.

Hochberg M, Martel-Pelletier J, Monfort J, Moller I, Castillo J, Arden N . Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis. 2015; 75(1):37-44. PMC: 4717399. DOI: 10.1136/annrheumdis-2014-206792. View